FORM 4

Check this box if no longer subject to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* PIMSTONE SIMON N.						2. Issuer Name and Ticker or Trading Symbol Xenon Pharmaceuticals Inc. [XENE]										k all applica	onship of Reporting Pers all applicable) Director		on(s) to Issu 10% Ov			
(Last) 200 - 365	(F 50 GILMOI	irst) RE WAY	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 05/24/2021										Officer (below)	Officer (give title below)		Other (s below)	pecify		
(Street) BURNA (City)		1 tate)	V5G 4W8 (Zip)	8	4.	4. If Amendment, Date of Original Filed (Month/Day/Year)										Form fil	idual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Та	ble I - No	n-Der	rivativ	ve Se	cur	ities A	cqı	uired,	Dis	posed of	, or Ben	efic	cially	Owned						
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					Execution Dat			,	3. Transaction Code (Instr. 8)		4. Securities Acquired Disposed Of (D) (Instr.				5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		Form (D) or	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
										Code	v	Amount	(A) or (D)						(instr. 4)			
Common Shares 05/24/2						2021				М		22,633	A	\$3	3.76(1)	232	32,819		D			
Common	Shares			05/2	24/202	21				F		5,076	D	\$1	9.17(2)	227	,743		D			
			Table II -									osed of, convertib				wned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution I if any (Month/Day	Date,		Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Date Exe piration I onth/Day	Date		7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		urity	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transactie (Instr. 4)	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Dat	te ercisable		xpiration ate	Title	or Nu of	mber ares							
Stock Option (Right to Buy)	\$3.76 ⁽¹⁾	05/24/2021			M			22,633		(3)	0	5/28/2021 ⁽⁴⁾	Common Shares	22	,633	\$0.00	0		D			

Explanation of Responses:

- 1. The exercise price was converted from \$3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.
- 2. Represents the closing price of the Company's common shares on May 21, 2021, which was converted to a Canadian dollar amount for purposes of net settlement calculations.
- 3. 25% of the shares subject to the Option vested on the one year anniversary of January 1, 2011 (the "2011 Vesting Commencement Date") and thereafter 1/48th of the shares subject to the Option vest on each monthly anniversary of the 2011 Vesting Commencement Date.
- 4. Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration date falling during a Company blackout period and a lock-up agreement period.

Remarks:

/s/ Cassandra Robinson,
Attorney-in-fact

05/26/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.